MetaCap

Corbus Pharmaceuticals (CRBP) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 41.4% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -94.0% for TLPH. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $40.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBP-82.85%TLPH-41.40%
+14%-37%-87%
Nov 21, 20251 yearNov 20, 2026
CRBP-92.63%TLPH-94.55%
+130%+11%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBP versus TLPH key metrics
MetricCRBPTLPH
Share price$2.06$0.7852
Market cap$42.45M$40.80M
1-day change-15.40%+6.25%
YTD return-74.69%-31.12%
1-year return-82.85%-41.40%
5-year return-92.23%-93.96%
EPS (TTM)$-6.04$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$28.00K
Net income (latest FY)$-78.54M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$12.88$1.57
52-week low$2.01$0.69
Distance from 52-week high-84.01%-49.99%
Analyst consensusstrong_buynone
Avg. price target upside+1551.94%+298.62%
Average volume1.11M144.13K
Shares outstanding20.61M51.96M
Employees3612
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed CRBP by 41.4 percentage points over the past year.

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CRBP vs TLPH FAQ

Which is bigger, Corbus Pharmaceuticals or Talphera?

Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $40.80M for Talphera (TLPH).

Which stock has performed better over the past year, CRBP or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Corbus Pharmaceuticals and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons